ASCO Conference Coverage
Featured Articles
(Forbes) June 7, 2018 - At the recently concluded annual meeting of the American Society of Clinical Oncology (ASCO) a group of researchers from Mexico City described a surprising discovery: In a phase 2 trial in patients with stage 4 lung cancer, a 24-year-old diabetes drug significantly improved survival when added to a standard...
Read Article
(The Center for Biosimilars) June 4, 2018 - During the 2018 American Society of Clinical Oncology's Annual Meeting, researchers presented findings on 3 biosimilar trastuzumab products: Samsung Bioepis’ SB3, Amgen’s ABP 980, and Biocad’s Herticad.
Read Article
Latest Articles
June 12, 2018
June 07, 2018
June 06, 2018
June 05, 2018
June 05, 2018
June 05, 2018
June 05, 2018
June 05, 2018
View More
News Commentary
Editor Image
17 May, 2018 | by H. Jack West, MD
It looks like we're going to have data from the IMpower150 trial released in...
View Comment
Editor Image
07 Jun, 2018 | by H. Jack West, MD
This work is certainly provocative, but there are several issues that should...
View Comment
View More
OBR Green
View More
OBR Blog
By Lynne Lederman, PhD On this final day of the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting we... Read more
June 05, 2018
by Lynne Lederman, PhD Several late-breaking abstracts were presented today at the 2018 American Society of Clinical... Read more
June 04, 2018